Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.
J Neurooncol. 2023 May;163(1):15-27. doi: 10.1007/s11060-023-04327-1. Epub 2023 May 8.
Stereotactic body radiotherapy (SBRT) has proven to be a highly effective treatment for selected patients with spinal metastases. Randomized evidence shows improvements in complete pain response rates and local control with lower retreatment rates favoring SBRT, compared to conventional external beam radiotherapy (cEBRT). While there are several reported dose-fractionation schemes for spine SBRT, 24 Gy in 2 fractions has emerged with Level 1 evidence providing an excellent balance between minimizing treatment toxicity while respecting patient convenience and financial strain.
We provide an overview of the 24 Gy in 2 SBRT fraction regimen for spine metastases, which was developed at the University of Toronto and tested in an international Phase 2/3 randomized controlled trial.
The literature summarizing global experience with 24 Gy in 2 SBRT fractions suggests 1-year local control rates ranging from 83-93.9%, and 1-year rates of vertebral compression fracture ranging from 5.4-22%. Reirradiation of spine metastases that failed prior cEBRT is also feasible with 24 Gy in 2 fractions, and 1-year local control rates range from 72-86%. Post-operative spine SBRT data are limited but do support the use of 24 Gy in 2 fractions with reported 1-year local control rates ranging from 70-84%. Typically, the rates of plexopathy, radiculopathy and myositis are under 5% in those series reporting mature follow up, with no cases of radiation myelopathy (RM) reported in the de novo setting when the spinal cord avoidance structure is limited to 17 Gy in 2 fractions. However, re-irradiation RM has been observed following 2 fraction SBRT. More recently, 2-fraction dose escalation with 28 Gy, with a higher dose constraint to the critical neural tissues, has been reported suggesting improved rates of local control. This regimen may be important in those patients with radioresistant histologies, high grade epidural disease, and/or paraspinal disease.
The dose-fractionation of 24 Gy in 2 fractions is well-supported by published literature and is an ideal starting point for centers looking to establish a spine SBRT program.
立体定向体放射治疗(SBRT)已被证明是治疗脊柱转移瘤的一种非常有效的方法。随机证据表明,与常规外照射放疗(cEBRT)相比,SBRT 可提高完全缓解疼痛的反应率和局部控制率,并降低复发率。虽然脊柱 SBRT 有几种报道的剂量分割方案,但 24 Gy 分 2 次的方案已被证明具有 1 级证据,在最大限度地减少治疗毒性的同时,兼顾了患者的便利性和经济压力。
我们提供了多伦多大学开发的脊柱转移瘤 24 Gy 分 2 次 SBRT 方案的概述,并在一项国际 2/3 期随机对照试验中进行了测试。
总结全球使用 24 Gy 分 2 次 SBRT 方案的文献表明,1 年局部控制率为 83-93.9%,1 年椎体压缩骨折率为 5.4-22%。对先前 cEBRT 失败的脊柱转移瘤进行再放疗也是可行的,24 Gy 分 2 次的 1 年局部控制率为 72-86%。术后脊柱 SBRT 的数据有限,但支持使用 24 Gy 分 2 次,报告的 1 年局部控制率为 70-84%。通常情况下,在那些报告成熟随访的系列中,多发性神经病、神经根病和肌炎的发生率低于 5%,在脊髓回避结构限制为 17 Gy 分 2 次的新发病例中没有报告放射性脊髓病(RM)。然而,在 2 次分割 SBRT 后观察到再放疗 RM。最近,有报道称 2 次分割剂量递增至 28 Gy,对关键神经组织的剂量限制更高,提示局部控制率提高。对于具有放射性耐药组织学、高级硬膜外疾病和/或脊柱旁疾病的患者,这种方案可能很重要。
24 Gy 分 2 次的剂量分割方案得到了已发表文献的充分支持,是那些希望建立脊柱 SBRT 项目的中心的理想起点。